{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:06Z","timestamp":1792788006126,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key supportive specialized construction project for the Health and Wellness System in Jinshan District, Shanghai","award":["(JSFCZK202102)."],"award-info":[{"award-number":["(JSFCZK202102)."]}]},{"name":"Natural Science Foundation of Shanghai","award":["23ZR1427400"],"award-info":[{"award-number":["23ZR1427400"]}]},{"name":"\u201cAI Empowerment for Research Program\u201d initiated by the Shanghai Municipal Education Commission","award":["(SHJWAIJK241205)"],"award-info":[{"award-number":["(SHJWAIJK241205)"]}],"id":[{"id":"https:\/\/ror.org\/05tewj457","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Construction project of Shanghai Key Laboratory of Molecular Imaging","award":["18DZ2260400"],"award-info":[{"award-number":["18DZ2260400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-03084-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:14:50Z","timestamp":1784272490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-recognizing antibodies targeting CEACAMs in the tumor microenvironment: towards more precise targeting"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiayi","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhai","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"3084_CR1","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753. Epub 2020 Nov 28. PMID: 33259885; PMCID: PMC8084948.","journal-title":"Pharmacol Ther"},{"issue":"13","key":"3084_CR2","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021;22(13):6995. https:\/\/doi.org\/10.3390\/ijms22136995. PMID: 34209703; PMCID: PMC8268869.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3084_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","volume":"17","author":"B Ren","year":"2018","unstructured":"Ren B, Cui M, Yang G, et al. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108. https:\/\/doi.org\/10.1186\/s12943-018-0858-1. PMID: 30060755; PMCID: PMC6065152.","journal-title":"Mol Cancer"},{"key":"3084_CR4","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1038\/srep05460","volume":"4","author":"H Li","year":"2014","unstructured":"Li H, Yang B, Xing K, et al. A preliminary study of the relationship between breast cancer metastasis and loss of heterozygosity by using exome sequencing. Sci Rep. 2014;4:5460.","journal-title":"Sci Rep"},{"key":"3084_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cytogfr.2019.05.008","volume":"47","author":"M Kelleher","year":"2019","unstructured":"Kelleher M, Singh R, O\u2019Driscoll CM, et al. Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease. Cytokine Growth Factor Rev. 2019;47:21\u201331. https:\/\/doi.org\/10.1016\/j.cytogfr.2019.05.008. Epub 2019 May 18. PMID: 31133507.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"13","key":"3084_CR6","doi-asserted-by":"publisher","first-page":"e2319055121","DOI":"10.1073\/pnas.2319055121","volume":"121","author":"J Michl","year":"2024","unstructured":"Michl J, White B, Monterisi S, et al. Phenotypic screen of sixty-eight colorectal cancer cell lines identifies CEACAM6 and CEACAM5 as markers of acid resistance. Proc Natl Acad Sci U S A. 2024;121(13):e2319055121. https:\/\/doi.org\/10.1073\/pnas.2319055121. Epub 2024 Mar 19. PMID: 38502695; PMCID: PMC10990159.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3084_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.7150\/ijbs.24505","volume":"14","author":"Q Li","year":"2018","unstructured":"Li Q, Li Y, Li J, et al. FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1\u03b1\/CEACAM5 functional axis. Int J Biol Sci. 2018;14(7):726\u201335. https:\/\/doi.org\/10.7150\/ijbs.24505. PMID: 29910683; PMCID: PMC6001674.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"3084_CR8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.ejca.2008.05.016","volume":"44","author":"JS Lewis-Wambi","year":"2008","unstructured":"Lewis-Wambi JS, Cunliffe HE, Kim HR, et al. Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer. 2008;44(12):1770\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2008.05.016. Epub 2008 Jul 7. PMID: 18614350; PMCID: PMC2778047.","journal-title":"Eur J Cancer"},{"key":"3084_CR9","doi-asserted-by":"publisher","first-page":"154215","DOI":"10.1016\/j.metabol.2020.154215","volume":"107","author":"J Liu","year":"2020","unstructured":"Liu J, Muturi HT, Khuder SS, et al. Loss of Ceacam1 promotes prostate cancer progression in Pten haploinsufficient male mice. Metabolism. 2020;107:154215. https:\/\/doi.org\/10.1016\/j.metabol.2020.154215. Epub 2020 Mar 21. PMID: 32209360; PMCID: PMC7283002.","journal-title":"Metabolism"},{"issue":"18","key":"3084_CR10","doi-asserted-by":"publisher","first-page":"e183676","DOI":"10.1172\/jci.insight.183676","volume":"10","author":"Y Ding","year":"2025","unstructured":"Ding Y, Yu A, Vujanac M, et al. BLIMP-1 and CEACAM1 cooperatively regulate human Treg homeostasis and function to control xenogeneic GVHD. JCI Insight. 2025;10(18):e183676. https:\/\/doi.org\/10.1172\/jci.insight.183676. PMID: 40773294; PMCID: PMC12487853.","journal-title":"JCI Insight"},{"key":"3084_CR11","unstructured":"Merck Announces First Patient Dosed in Phase. 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer. https:\/\/www.merckgroup.com\/en\/news\/precem-tct-phase-3-first-dose-21-05-2026.html. Accessed 20 June 2026."},{"key":"3084_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cytogfr.2019.05.008","volume":"47","author":"M Kelleher","year":"2019","unstructured":"Kelleher M, Singh R, O\u2019Driscoll CM, et al. Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease. Cytokine Growth Factor Rev. 2019;47:21\u201331. https:\/\/doi.org\/10.1016\/j.cytogfr.2019.05.008. Epub 2019 May 18. PMID: 31133507.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"3084_CR13","doi-asserted-by":"publisher","first-page":"e14357","DOI":"10.1111\/eci.14357","volume":"54","author":"AK Gandhi","year":"2024","unstructured":"Gandhi AK, Huang YH, Sun ZJ, et al. Structural aspects of CEACAM1 interactions. Eur J Clin Invest. 2024;54(2):e14357. https:\/\/doi.org\/10.1111\/eci.14357. Epub 2024 Nov 18. PMID: 39555955; PMCID: PMC12938038.","journal-title":"Eur J Clin Invest"},{"key":"3084_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s42003-021-01871-2","volume":"4","author":"AK Gandhi","year":"2021","unstructured":"Gandhi AK, Sun ZYJ, Kim WM, et al. Structural basis of the dynamic human CEACAM1 monomer-dimer equilibrium. Commun Biol. 2021;4:360. https:\/\/doi.org\/10.1038\/s42003-021-01871-2.","journal-title":"Commun Biol"},{"key":"3084_CR15","doi-asserted-by":"publisher","unstructured":"Bonsor DA, G\u00fcnther S, Beadenkopf R. D. Diverse oligomeric states of CEACAM IgV domains, Proc. Natl. Acad. Sci. U.S.A. 2015;112(44):13561\u201313566. https:\/\/doi.org\/10.1073\/pnas.1509511112.","DOI":"10.1073\/pnas.1509511112"},{"key":"3084_CR16","doi-asserted-by":"publisher","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3\u20134):643\u2009\u2013\u200971. https:\/\/doi.org\/10.1007\/s10555-013-9444-6. PMID: 23903773.","DOI":"10.1007\/s10555-013-9444-6"},{"issue":"44","key":"3084_CR17","doi-asserted-by":"publisher","first-page":"13561","DOI":"10.1073\/pnas.1509511112","volume":"112","author":"DA Bonsor","year":"2015","unstructured":"Bonsor DA, G\u00fcnther S, Beadenkopf R, et al. Diverse oligomeric states of CEACAM IgV domains. Proc Natl Acad Sci U S A. 2015;112(44):13561\u20136. https:\/\/doi.org\/10.1073\/pnas.1509511112. Epub 2015 Oct 19. PMID: 26483485; PMCID: PMC4640789.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3084_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ceb.2006.08.008","volume":"18","author":"K Kuespert","year":"2006","unstructured":"Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18(5):565\u201371. https:\/\/doi.org\/10.1016\/j.ceb.2006.08.008. Epub 2006 Aug 17. PMID: 16919437; PMCID: PMC7127089.","journal-title":"Curr Opin Cell Biol"},{"key":"3084_CR19","doi-asserted-by":"publisher","unstructured":"Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433\u2009\u2013\u200946. https:\/\/doi.org\/10.1038\/nri1864. PMID: 16724098.","DOI":"10.1038\/nri1864"},{"issue":"D1","key":"3084_CR20","doi-asserted-by":"publisher","first-page":"D891","DOI":"10.1093\/nar\/gkad1049","volume":"52","author":"PW Harrison","year":"2024","unstructured":"Harrison PW, Amode MR, Austine-Orimoloye O, et al. Ensembl 2024. Nucleic Acids Res. 2024;52(D1):D891\u20139. https:\/\/doi.org\/10.1093\/nar\/gkad1049. PMID: 37953337; PMCID: PMC10767893.","journal-title":"Nucleic Acids Res"},{"key":"3084_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1476-4598-7-46","volume":"7","author":"S Gaur","year":"2008","unstructured":"Gaur S, Shively JE, Yen Y, et al. Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms. Mol Cancer. 2008;7:46. https:\/\/doi.org\/10.1186\/1476-4598-7-46. PMID: 18507857; PMCID: PMC2490704.","journal-title":"Mol Cancer"},{"key":"3084_CR22","doi-asserted-by":"publisher","unstructured":"Chen D, Iijima H, Nagaishi T et al. Carcinoembryonic antigen-related cellular adhesion molecule 1 isoforms alternatively inhibit and costimulate human T cell function. J Immunol. 2004;172(6):3535-43. https:\/\/doi.org\/10.4049\/jimmunol.172.6.3535. PMID: 15004154.","DOI":"10.4049\/jimmunol.172.6.3535"},{"key":"3084_CR23","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.3389\/fimmu.2019.03160","volume":"10","author":"P Bonsignore","year":"2020","unstructured":"Bonsignore P, Kuiper JWP, Adrian J, et al. CEACAM3-A Prim(at)e Invention for Opsonin-Independent Phagocytosis of Bacteria. Front Immunol. 2020;10:3160. https:\/\/doi.org\/10.3389\/fimmu.2019.03160. PMID: 32117212; PMCID: PMC7026191.","journal-title":"Front Immunol"},{"issue":"2","key":"3084_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3747\/co.2007.109","volume":"14","author":"CH Chan","year":"2007","unstructured":"Chan CH, Stanners CP. Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6. Curr Oncol. 2007;14(2):70\u20133. https:\/\/doi.org\/10.3747\/co.2007.109. PMID: 17576469; PMCID: PMC1891201.","journal-title":"Curr Oncol"},{"key":"3084_CR25","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.mam.2020.100870","volume":"80","author":"S Sivori","year":"2021","unstructured":"Sivori S, Pende D, Quatrini L, et al. NK cells and ILCs in tumor immunotherapy. Mol Aspects Med. 2021;80:100870. https:\/\/doi.org\/10.1016\/j.mam.2020.100870. Epub 2020 Aug 13. PMID: 32800530.","journal-title":"Mol Aspects Med"},{"issue":"1","key":"3084_CR26","doi-asserted-by":"publisher","first-page":"e000301","DOI":"10.1136\/jitc-2019-000301","volume":"8","author":"DJ Park","year":"2020","unstructured":"Park DJ, Sung PS, Kim JH, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer. 2020;8(1):e000301. https:\/\/doi.org\/10.1136\/jitc-2019-000301. PMID: 32221015; PMCID: PMC7206970.","journal-title":"J Immunother Cancer"},{"key":"3084_CR27","doi-asserted-by":"publisher","unstructured":"Izzi L, Turbide C, Houde C, Kunath T, Beauchemin N. cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function. Oncogene. 1999;18(40):5563-72. https:\/\/doi.org\/10.1038\/sj.onc.1202935. PMID: 10523833.","DOI":"10.1038\/sj.onc.1202935"},{"issue":"7","key":"3084_CR28","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/eji.201445151","volume":"45","author":"W Merkt","year":"2015","unstructured":"Merkt W, Urlaub D, Meinke S, Kammerer R, Watzl C. Inhibition of NKp30- and 2B4-mediated NK cell activation by evolutionary different human and bovine CEACAM1 receptors. Eur J Immunol. 2015;45(7):2134\u201342. https:\/\/doi.org\/10.1002\/eji.201445151. Epub 2015 Apr 22. PMID: 25824372.","journal-title":"Eur J Immunol"},{"issue":"6","key":"3084_CR29","doi-asserted-by":"publisher","first-page":"e21146","DOI":"10.1371\/journal.pone.0021146","volume":"6","author":"C Zheng","year":"2011","unstructured":"Zheng C, Feng J, Lu D, Wang P, Xing S, Coll JL, Yang D, Yan X. A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity. PLoS ONE. 2011;6(6):e21146. https:\/\/doi.org\/10.1371\/journal.pone.0021146. Epub 2011 Jun 22. PMID: 21731662; PMCID: PMC3120848.","journal-title":"PLoS ONE"},{"issue":"13","key":"3084_CR30","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1084\/jem.20102575","volume":"208","author":"Z Chen","year":"2011","unstructured":"Chen Z, Chen L, Baker K, Olszak T, Zeissig S, Huang YH, Kuo TT, Mandelboim O, Beauchemin N, Lanier LL, Blumberg RS. CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med. 2011;208(13):2633\u201340. https:\/\/doi.org\/10.1084\/jem.20102575. Epub 2011 Dec 5. PMID: 22143889; PMCID: PMC3244030.","journal-title":"J Exp Med"},{"issue":"9","key":"3084_CR31","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/0008-5472.CAN-14-1752","volume":"75","author":"N Ullrich","year":"2015","unstructured":"Ullrich N, Heinemann A, Nilewski E, et al. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Res. 2015;75(9):1897\u2013907. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1752. Epub 2015 Mar 5. PMID: 25744717.","journal-title":"Cancer Res"},{"issue":"4","key":"3084_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.trecan.2024.12.002","volume":"11","author":"J Hochstadt","year":"2025","unstructured":"Hochstadt J, Mart\u00ednez Pacheco S, Casanova-Acebes M. Embracing diversity: macrophage complexity in cancer. Trends Cancer. 2025;11(4):351\u201364. https:\/\/doi.org\/10.1016\/j.trecan.2024.12.002. Epub 2025 Jan 2. PMID: 39753470.","journal-title":"Trends Cancer"},{"issue":"16","key":"3084_CR33","doi-asserted-by":"publisher","first-page":"e2103230","DOI":"10.1002\/advs.202103230","volume":"9","author":"SKY To","year":"2022","unstructured":"To SKY, Tang MKS, Tong Y, et al. A Selective \u03b2-Catenin-Metadherin\/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction. Adv Sci (Weinh). 2022;9(16):e2103230. https:\/\/doi.org\/10.1002\/advs.202103230. Epub 2022 Apr 11. PMID: 35403834; PMCID: PMC9165500.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"3084_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/ijc.28036","volume":"133","author":"S Samineni","year":"2013","unstructured":"Samineni S, Zhang Z, Shively JE. Carcinoembryonic antigen-related cell adhesion molecule 1 negatively regulates granulocyte colony-stimulating factor production by breast tumor-associated macrophages that mediate tumor angiogenesis. Int J Cancer. 2013;133(2):394\u2013407. https:\/\/doi.org\/10.1002\/ijc.28036. Epub 2013 Feb 12. PMID: 23319418; PMCID: PMC3838202.","journal-title":"Int J Cancer"},{"issue":"1","key":"3084_CR35","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1038\/s41467-018-04832-2","volume":"9","author":"V Khairnar","year":"2018","unstructured":"Khairnar V, Duhan V, Patil AM, et al. CEACAM1 promotes CD8\u2009+\u2009T cell responses and improves control of a chronic viral infection. Nat Commun. 2018;9(1):2561. https:\/\/doi.org\/10.1038\/s41467-018-04832-2. PMID: 29967450; PMCID: PMC6028648.","journal-title":"Nat Commun"},{"issue":"8","key":"3084_CR36","doi-asserted-by":"publisher","first-page":"101686","DOI":"10.1016\/j.xcrm.2024.101686","volume":"5","author":"C Chen","year":"2024","unstructured":"Chen C, Zhao F, Peng J, et al. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8\u2009+\u2009T cell exhaustion and anti-PD-1 resistance. Cell Rep Med. 2024;5(8):101686. PMID: 39168104; PMCID: PMC11384939.","journal-title":"Cell Rep Med"},{"issue":"5","key":"3084_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2006.08.026","volume":"25","author":"T Nagaishi","year":"2006","unstructured":"Nagaishi T, Pao L, Lin SH, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity. 2006;25(5):769\u201381. https:\/\/doi.org\/10.1016\/j.immuni.2006.08.026. Epub 2006 Nov 2. PMID: 17081782.","journal-title":"Immunity"},{"key":"3084_CR38","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1038\/s41467-025-60208-3","volume":"16","author":"S Xavier","year":"2025","unstructured":"Xavier S, Nguyen V, Khairnar V, et al. CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma. Nat Commun. 2025;16:4967.","journal-title":"Nat Commun"},{"issue":"4","key":"3084_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41419-021-03689-6","volume":"12","author":"CM Lake","year":"2021","unstructured":"Lake CM, Voss K, Bauman BM, Pohida K, et al. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8\u2009+\u2009T cells in conjunction with CEACAM1. Cell Death Dis. 2021;12(4):400. https:\/\/doi.org\/10.1038\/s41419-021-03689-6. PMID: 33854046; PMCID: PMC8046753.","journal-title":"Cell Death Dis"},{"issue":"9","key":"3084_CR40","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1158\/1078-0432.CCR-22-1843","volume":"29","author":"SH Jeon","year":"2023","unstructured":"Jeon SH, Kang M, Jeon M, et al. CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy. Clin Cancer Res. 2023;29(9):1794\u2013806. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1843. PMID: 36716293.","journal-title":"Clin Cancer Res"},{"key":"3084_CR41","doi-asserted-by":"publisher","unstructured":"Jeon SH, Kang M, Jeon M et al. CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy. Clin Cancer Res. 2023;29(9):1794\u20131806. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1843. PMID: 36716293.","DOI":"10.1158\/1078-0432.CCR-22-1843"},{"key":"3084_CR42","doi-asserted-by":"publisher","first-page":"1662004","DOI":"10.3389\/fimmu.2025.1662004","volume":"16","author":"D Fang","year":"2025","unstructured":"Fang D, Lin J, Wang J, et al. CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+\/HER2- breast cancer. Front Immunol. 2025;16:1662004. https:\/\/doi.org\/10.3389\/fimmu.2025.1662004. PMID: 40936892; PMCID: PMC12420257.","journal-title":"Front Immunol"},{"issue":"18","key":"3084_CR43","doi-asserted-by":"publisher","first-page":"e183676","DOI":"10.1172\/jci.insight.183676","volume":"10","author":"Y Ding","year":"2025","unstructured":"Ding Y, Yu A, Vujanac M, et al. BLIMP-1 and CEACAM1 cooperatively regulate human Treg homeostasis and function to control xenogeneic GVHD. JCI Insight. 2025;10(18):e183676. https:\/\/doi.org\/10.1172\/jci.insight.183676. PMID: 40773294; PMCID: PMC12487853.","journal-title":"JCI Insight"},{"issue":"1","key":"3084_CR44","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1038\/s41467-025-60208-3","volume":"16","author":"S Xavier","year":"2025","unstructured":"Xavier S, Nguyen V, Khairnar V, et al. CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma. Nat Commun. 2025;16(1):4967. https:\/\/doi.org\/10.1038\/s41467-025-60208-3. PMID: 40436855; PMCID: PMC12120064.","journal-title":"Nat Commun"},{"issue":"5","key":"3084_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jmb.2012.09.025","volume":"424","author":"W Suphamungmee","year":"2012","unstructured":"Suphamungmee W, Nakamura F, Hartwig JH, et al. Electron microscopy and 3D reconstruction reveals filamin Ig domain binding to F-actin. J Mol Biol. 2012;424(5):248\u201356. https:\/\/doi.org\/10.1016\/j.jmb.2012.09.025. Epub 2012 Oct 4. PMID: 23041423; PMCID: PMC3502691.","journal-title":"J Mol Biol"},{"key":"3084_CR46","doi-asserted-by":"publisher","unstructured":"e M, Lu F, Gu D et al. Hypoxia exosome derived CEACAM5 promotes tumor-associated macrophages M2 polarization to accelerate pancreatic neuroendocrine tumors metastasis via MMP9. FASEB J. 2024;38(13):e23762. https:\/\/doi.org\/10.1096\/fj.202302489RRR. PMID: 38923643.","DOI":"10.1096\/fj.202302489RRR"},{"issue":"Suppl 2","key":"3084_CR47","doi-asserted-by":"publisher","first-page":"e14352","DOI":"10.1111\/eci.14352","volume":"54","author":"I Poirah","year":"2024","unstructured":"Poirah I, Chakraborty D, Dixit P, et al. The influence of hypoxia-mediated CEACAM6 upregulation on epithelial cell and macrophage response in the context of gastric cancer. Eur J Clin Invest. 2024;54(Suppl 2):e14352. https:\/\/doi.org\/10.1111\/eci.14352. PMID: 39674878; PMCID: PMC11646287.","journal-title":"Eur J Clin Invest"},{"key":"3084_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.acr.2014.11.004","volume":"126","author":"S Holst","year":"2015","unstructured":"Holst S, Wuhrer M, Rombouts Y. Glycosylation characteristics of colorectal cancer. Adv Cancer Res. 2015;126:203\u201356. https:\/\/doi.org\/10.1016\/bs.acr.2014.11.004. Epub 2015 Feb 7. PMID: 25727149.","journal-title":"Adv Cancer Res"},{"key":"3084_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1478-811X-12-27","volume":"12","author":"AK Tchoupa","year":"2014","unstructured":"Tchoupa AK, Schuhmacher T, Hauck CR. Signaling by epithelial members of the CEACAM family - mucosal docking sites for pathogenic bacteria. Cell Commun Signal. 2014;12:27. https:\/\/doi.org\/10.1186\/1478-811X-12-27. PMID: 24735478; PMCID: PMC4057559.","journal-title":"Cell Commun Signal"},{"key":"3084_CR50","doi-asserted-by":"publisher","unstructured":"Ordonez C, Zhai AB, Camacho-Leal P et al. GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol. 2007;210(3):757\u2009\u2013\u200965. https:\/\/doi.org\/10.1002\/jcp.20887. PMID: 17167768.","DOI":"10.1002\/jcp.20887"},{"issue":"1","key":"3084_CR51","doi-asserted-by":"publisher","first-page":"18347","DOI":"10.1038\/s41598-019-54545-9","volume":"9","author":"R Pandey","year":"2019","unstructured":"Pandey R, Zhou M, Islam S, et al. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Sci Rep. 2019;9(1):18347. https:\/\/doi.org\/10.1038\/s41598-019-54545-9. PMID: 31797958; PMCID: PMC6893022.","journal-title":"Sci Rep"},{"issue":"1","key":"3084_CR52","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13046-021-01946-2","volume":"40","author":"M Kemper","year":"2021","unstructured":"Kemper M, Schiecke A, Maar H, et al. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. J Exp Clin Cancer Res. 2021;40(1):214. https:\/\/doi.org\/10.1186\/s13046-021-01946-2. PMID: 34174926; PMCID: PMC8235815.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"3084_CR53","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/ijc.31586","volume":"143","author":"A Abdul-Wahid","year":"2018","unstructured":"Abdul-Wahid A, Cydzik M, Fischer NW, et al. Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. Int J Cancer. 2018;143(8):1963\u201377. https:\/\/doi.org\/10.1002\/ijc.31586. Epub 2018 Aug 9. PMID: 29756328; PMCID: PMC6128780.","journal-title":"Int J Cancer"},{"issue":"8","key":"3084_CR54","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc2353","volume":"8","author":"CJ Avraamides","year":"2008","unstructured":"Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8(8):604\u201317. https:\/\/doi.org\/10.1038\/nrc2353. Epub 2008 May 22. PMID: 18497750; PMCID: PMC2577722.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3084_CR55","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1161\/ATVBAHA.115.306133","volume":"35","author":"C Krawutschke","year":"2015","unstructured":"Krawutschke C, Koesling D, Russwurm M. Cyclic GMP in Vascular Relaxation: Export Is of Similar Importance as Degradation. Arterioscler Thromb Vasc Biol. 2015;35(9):2011\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306133. Epub 2015 Jul 23. PMID: 26205960.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"41","key":"3084_CR56","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1038\/onc.2011.146","volume":"30","author":"D Gerstel","year":"2011","unstructured":"Gerstel D, Wegwitz F, Jannasch K, et al. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene. 2011;30(41):4275\u201388. https:\/\/doi.org\/10.1038\/onc.2011.146. Epub 2011 May 2. PMID: 21532628.","journal-title":"Oncogene"},{"issue":"13","key":"3084_CR57","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1182\/blood-2007-06-097592","volume":"110","author":"N Kilic","year":"2007","unstructured":"Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, et al. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1. Blood. 2007;110(13):4223\u201333. https:\/\/doi.org\/10.1182\/blood-2007-06-097592. Epub 2007 Aug 30. PMID: 17761831.","journal-title":"Blood"},{"key":"3084_CR58","doi-asserted-by":"publisher","unstructured":"Poliani PL, Mitola S, Ravanini M et al. CEACAM1\/VEGF cross-talk during neuroblastic tumour differentiation. J Pathol. 2007;211(5):541\u2013549. https:\/\/doi.org\/10.1002\/path.2135. PMID: 17310502.","DOI":"10.1002\/path.2135"},{"issue":"36","key":"3084_CR59","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1038\/sj.onc.1209514","volume":"25","author":"D Tilki","year":"2006","unstructured":"Tilki D, Irmak S, Oliveira-Ferrer L, et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene. 2006;25(36):4965\u201374. https:\/\/doi.org\/10.1038\/sj.onc.1209514. Epub 2006 Mar 27. PMID: 16568082.","journal-title":"Oncogene"},{"issue":"7","key":"3084_CR60","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/sj.bjc.6602113","volume":"91","author":"MS Duxbury","year":"2004","unstructured":"Duxbury MS, Ito H, Benoit E, Ashley SW, Whang EE. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer. 2004;91(7):1384\u201390. https:\/\/doi.org\/10.1038\/sj.bjc.6602113. PMID: 15316565; PMCID: PMC2409898.","journal-title":"Br J Cancer"},{"key":"3084_CR61","unstructured":"CM-24. https:\/\/purple-biotech.com\/pipeline\/cm24\/."},{"key":"3084_CR62","doi-asserted-by":"publisher","unstructured":"Zaffran I, Landolina N, Gaur P et al. Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Ther. 2022;29(11):1676\u20131685. https:\/\/doi.org\/10.1038\/s41417-022-00486-x. Epub 2022 Jun 9. Erratum in: Cancer Gene Ther. 2023;30(6):926. doi: 10.1038\/s41417-023-00594-2. PMID: 35681020.","DOI":"10.1038\/s41417-022-00486-x"},{"issue":"Pt 2","key":"3084_CR63","doi-asserted-by":"publisher","first-page":"113395","DOI":"10.1016\/j.intimp.2024.113395","volume":"143","author":"L Zhao","year":"2024","unstructured":"Zhao L, Li T, Zhou Y, et al. Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer. Int Immunopharmacol. 2024;143(Pt 2):113395. https:\/\/doi.org\/10.1016\/j.intimp.2024.113395. Epub 2024 Oct 18. PMID: 39426236.","journal-title":"Int Immunopharmacol"},{"key":"3084_CR64","doi-asserted-by":"publisher","unstructured":"Cole CB, Morelli MP, Fantini M et al. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. J Exp Clin Cancer Res. 2023;42(1):76. https:\/\/doi.org\/10.1186\/s13046-023-02649-6. PMID: 36991390; PMCID: PMC10053355.","DOI":"10.1186\/s13046-023-02649-6"},{"key":"3084_CR65","doi-asserted-by":"publisher","unstructured":"Siu LL, Hong DS, D\u00f6cke WD et al. A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors. Target Oncol. 2025;20(4):637\u2013649. https:\/\/doi.org\/10.1007\/s11523-025-01154-4. Epub 2025 Jun 4. PMID: 40465170.","DOI":"10.1007\/s11523-025-01154-4"},{"key":"3084_CR66","unstructured":"Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2023\/2023-12-21-06-30-00-2799759.\u00a0Accessed 23 June 2026."},{"key":"3084_CR67","unstructured":"Matthew CH, Ng WP Yong2, Bernstam F-M 3 et al. A Phase 1 dose escalation study of ebc-129, a first-in class, anti n-glycosylated ceacam5 & ceacam6 antibody-drug conjugate (ADC) in patients with solid tumors. https:\/\/www.eddc.sg\/wp-content\/uploads\/2024\/09\/ESMO-2024-A-Phase-1-Dose-Escalation-Study-Of-EBC-129.pdf"},{"key":"3084_CR68","doi-asserted-by":"publisher","unstructured":"Nakazawa Y, Miyano M, Tsukamoto S, et al. Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models. Nat Commun. 2024;15(1):2192. https:\/\/doi.org\/10.1038\/s41467-024-461671.","DOI":"10.1038\/s41467-024-461671"},{"key":"3084_CR69","doi-asserted-by":"publisher","unstructured":"Seckinger A, Majocchi S, Moine V et al. Development and characterization of NILK-2301, a novel CEACAM5xCD3 \u03ba\u03bb bispecific antibody for immunotherapy of CEACAM5-expressing cancers. J Hematol Oncol. 2023;16(1):117. https:\/\/doi.org\/10.1186\/s13045-023-01516-3. PMID: 38087365.","DOI":"10.1186\/s13045-023-01516-3"},{"key":"3084_CR70","doi-asserted-by":"publisher","first-page":"1378813","DOI":"10.3389\/fimmu.2024.1378813","volume":"15","author":"A Seckinger","year":"2024","unstructured":"Seckinger A, Buatois V, Moine V, et al. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 \u03ba\u03bb bispecific antibody. Front Immunol. 2024;15:1378813. https:\/\/doi.org\/10.3389\/fimmu.2024.1378813. PMID: 38720892; PMCID: PMC11076849.","journal-title":"Front Immunol"},{"issue":"11","key":"3084_CR71","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66(11):1425\u201336. https:\/\/doi.org\/10.1007\/s00262-017-2034-7. Epub 2017 Jun 28. PMID: 28660319; PMCID: PMC5645435.","journal-title":"Cancer Immunol Immunother"},{"key":"3084_CR72","unstructured":"Dual-Target CAR-NK. Cells for Biomarker-Selected Advanced Colorectal Cancer. https:\/\/clinicaltrials.gov\/study\/NCT07462650?intr=CEACAM5&viewType=Card&rank=1 Accessed 26 June 2026."},{"issue":"10","key":"3084_CR73","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/ijms19103110","volume":"19","author":"AK Horst","year":"2018","unstructured":"Horst AK, Najjar SM, Wagener C, et al. CEACAM1 in Liver Injury, Metabolic and Immune Regulation. Int J Mol Sci. 2018;19(10):3110. https:\/\/doi.org\/10.3390\/ijms19103110. PMID: 30314283; PMCID: PMC6213298.","journal-title":"Int J Mol Sci"},{"key":"3084_CR74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/genesandcancer.230","volume":"14","author":"J Thomas","year":"2023","unstructured":"Thomas J, Klebanov A, John S, et al. CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens. Genes Cancer. 2023;14:12\u201329. https:\/\/doi.org\/10.18632\/genesandcancer.230. PMID: 36741860; PMCID: PMC9891707.","journal-title":"Genes Cancer"},{"key":"3084_CR75","doi-asserted-by":"publisher","unstructured":"Bramswig KH, Poettler M, Unseld M et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res. 2013;73(22):6584-96. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0123. Epub 2013 Oct 11. PMID: 24121495.","DOI":"10.1158\/0008-5472.CAN-13-0123"},{"key":"3084_CR76","doi-asserted-by":"publisher","unstructured":"Scheuher B, et al. Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results. medRxiv. 2026;2026013026345218. https:\/\/doi.org\/10.64898\/2026.01.30.26345218.","DOI":"10.64898\/2026.01.30.26345218"},{"issue":"24","key":"3084_CR77","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, Berne PF, Nicolazzi C, et al. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Clin Cancer Res. 2020;26(24):6589\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4051. Epub 2020 Oct 12. PMID: 33046521.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3084_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ijc.26354","volume":"131","author":"E Saeland","year":"2012","unstructured":"Saeland E, Belo AI, Mongera S, et al. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int J Cancer. 2012;131(1):117\u201328. https:\/\/doi.org\/10.1002\/ijc.26354. Epub 2011 Nov 28. PMID: 21823122.","journal-title":"Int J Cancer"},{"issue":"3","key":"3084_CR79","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1021\/acs.jproteome.0c00875","volume":"20","author":"L Pont","year":"2021","unstructured":"Pont L, Kuzyk V, Benavente F, et al. Site-Specific N-Linked Glycosylation Analysis of Human Carcinoembryonic Antigen by Sheathless Capillary Electrophoresis-Tandem Mass Spectrometry. J Proteome Res. 2021;20(3):1666\u201375. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00875. Epub 2021 Feb 9. PMID: 33560857; PMCID: PMC8023805.","journal-title":"J Proteome Res"},{"issue":"22","key":"3084_CR80","doi-asserted-by":"publisher","first-page":"10056","DOI":"10.1073\/pnas.0915176107","volume":"107","author":"CL Brooks","year":"2010","unstructured":"Brooks CL, Schietinger A, Borisova SN, et al. Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A. 2010;107(22):10056\u201361. https:\/\/doi.org\/10.1073\/pnas.0915176107. Epub 2010 May 17. PMID: 20479270; PMCID: PMC2890472.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3084_CR81","doi-asserted-by":"crossref","unstructured":"Frey G, Cugnetti APG, Liu H et al. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy. MAbs. 2024 Jan-Dec;16(1):2322562. doi: 10.1080\/19420862.2024.2322562. Epub 2024 Mar 6. PMID: 38445633.","DOI":"10.1080\/19420862.2024.2322562"},{"issue":"1","key":"3084_CR82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-025-00624-9","volume":"14","author":"M Luo","year":"2025","unstructured":"Luo M, Wang X, Yu G, et al. Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors. Exp Hematol Oncol. 2025;14(1):33. https:\/\/doi.org\/10.1186\/s40164-025-00624-9. PMID: 40057807; PMCID: PMC11889805.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"3084_CR83","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.annonc.2026.01.009","volume":"37","author":"SD Hong","year":"2026","unstructured":"Hong SD, Wang YS, Zhao HY, et al. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol. 2026;37(6):813\u201324. Epub 2026 Jan 27. PMID: 41611210.","journal-title":"Ann Oncol"},{"issue":"7","key":"3084_CR84","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nsmb.2600","volume":"20","author":"M Pancera","year":"2013","unstructured":"Pancera M, Shahzad-Ul-Hussan S, Doria-Rose, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013;20(7):804\u201313. https:\/\/doi.org\/10.1038\/nsmb.2600. Epub 2013 May 26. PMID: 23708607; PMCID: PMC4046252.","journal-title":"Nat Struct Mol Biol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03084-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:33:00Z","timestamp":1791847980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-03084-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3084"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03084-8","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"546"}}